GlassScriptPhysician profile
Ronald Frank Marascalco
NPI 1649389651
$2,579.14
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,313 · 2022: $266.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $535.18 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $462.79 | 2021-2022 | |
| Ucb, INC. | $319.56 | 2021-2022 | |
| Amgen INC. | $266.33 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $249.70 | 2021 | |
| Pfizer INC. | $208.90 | 2021 | |
| Genzyme Corporation | $148.70 | 2021 | |
| Janssen Biotech, INC. | $122.60 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $72.86 | 2021 | |
| Vyne Pharmaceuticals INC. | $47.69 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.11 | 2021 | |
| Leo Pharma INC. | $29.86 | 2021 | |
| Mayne Pharma Commercial LLC | $24.49 | 2021 | |
| Almirall LLC | $20.37 | 2021 | |
| Lilly USA, LLC | $17.01 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $16.99 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Marascalco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.